PSMA PET could be used for dose escalation to avid lesions, as per the FLAME study (which used MRI rather than PSMA PET) [77,78], given the high correlation between PET avidity and tumor aggressiveness on histopathology [79,80]. Here, FOLH1 is linked to neoplasm.